Back to Cell Types

PF-382Homo sapiens (Human)Cancer cell line

Also known as: PF382

🤖 AI SummaryBased on 9 publications

Quick Overview

Human T-cell acute lymphoblastic leukemia cell line with unique TCR profiles and potential for immunotherapy research.

Detailed Summary

PF-382 is a human T-cell acute lymphoblastic leukemia (T-ALL) cell line derived from a child with T-ALL. It exhibits a distinct T-cell receptor (TCR) gene rearrangement profile, making it a valuable tool for studying TCR-mediated clonality and immunotherapy. The cell line has a modal chromosome number of 46 and carries a specific chromosomal translocation between chromosome X and 15 (46Xq,-15p+15). PF-382 shows characteristics of suppressor lymphocytes, including the expression of the OKT8 antigen and the ability to modulate B-cell differentiation. It does not exhibit cytotoxic activity against NK-sensitive targets, suggesting it does not represent NK cells. The cell line is also notable for its lack of IL-2 and IFN production, which may indicate an immature or dysfunctional state. PF-382 has been used in studies related to T-cell differentiation, immunomodulation, and cancer immunotherapy.

Research Applications

Immunotherapy researchT-cell receptor (TCR) clonality studiesCancer immunologyT-cell differentiationImmunomodulation

Key Characteristics

Distinct TCR gene rearrangement profileChromosomal translocation (X;15)Expression of OKT8 antigenSuppressor lymphocyte activityLack of IL-2 and IFN production

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1641
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	6
Age Category	Pediatric
Sex	Female
Subtype Features	TAL1

Disease Information

Disease	Precursor T-cell acute lymphoblastic leukemia
Lineage	Lymphoid
Subtype	T-Lymphoblastic Leukemia/Lymphoma
OncoTree Code	TLL

DepMap Information

Source Type	DSMZ
Source ID	ACH-000937_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273Cys (c.817C>T)	Homozygous	-	PubMed=35933914
MutationSimple	NOTCH1	p.Pro2493fs*67 (c.7476_7477ins11)	Heterozygous	-	from parent cell line PF-382
MutationSimple	NOTCH1	p.Leu1574Pro (c.4721T>C)	Heterozygous	-	from parent cell line PF-382

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,13

D13S317

11,12

D16S539

9,12

D18S51

14

D19S433

13,15

D21S11

29,32.2

D2S1338

17,25

D3S1358

15,16

D5S818

11,12

D7S820

9,10

D8S1179

12,15

FGA

21

Penta D

11,12

Penta E

5,17

TH01

6,9.3

TPOX

11

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Lehtio J., Vesterlund M., Jafari R.

Nat. Commun. 13:1691.1-1691.19(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Langerak A.W.

Leukemia 21:230-237(2007).

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.

Science 306:269-271(2004).

A human leukemic T cell line (PF-382) inhibits the growth of myeloid and erythroid progenitor cells.

Lista P., Ghio R., Pegoraro L.

Leukemia 1:603-608(1987).

A human acute leukemia-derived T-cell line produces two inhibitor factors which suppress lymphocyte proliferation: characterization and purification of the molecules.

Cornaglia-Ferraris P., Ponzoni M.

Lymphokine Res. 7:413-427(1988).

A novel leukemia T-cell line (PF-382) with phenotypic and functional features of suppressor lymphocytes.

Giovarelli M., Matera L., Foa R.

J. Natl. Cancer Inst. 75:285-290(1985).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).